News and Press Releases
Company announcements and independent coverage, from the first Amgen Golden Ticket awarded in Singapore to the arthritis data published in Nature Communications.
Nature Communications Publishes Pivotal Data From Albatroz Therapeutics Demonstrating That Inhibiting Calnexin Alleviates Arthritis Symptoms and May Reverse Disease Progression
Albatroz Therapeutics Soars in “Leading Biotech Companies in Singapore 2025” List
Albatroz Therapeutics Soars into Johnson & Johnson Innovation – JLABS Singapore
Albatroz Co-Founder and CEO, Dr. Frederic Bard is spotlighted by A*STAR – Agency for Science, Technology and Research for his insights as a scientist-entrepreneur
Albatroz Named One of Six Companies Leading Singapore’s Biotech Scene
Albatroz Featured in the Novo Nordisk Singapore Partnering Day 2023
Albatroz Co-Founder Presents at the ‘Biomedical Innovation in Asia’ Workshop
In Vivo Spotlights Albatroz’s Science and the Leadership of Guy Heathers
BioWorld Recognizes Albatroz Science, Leadership, and Progress Toward Blocking a Highly Specific Target to Block Growth and Spread of Solid Tumors and Cartilage Degradation
Albatroz Therapeutics Secure $3 Million to Develop First-ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation
Albatroz Therapeutics Featured in A*STAR Research Highlights
